Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $27

Goldman Sachs analyst Corinne Jenkins initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price Target of $27.
byBenzinga Newsdesk
December 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Corinne Jenkins initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price Target of $27.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts